Pediatric oncology enters an era of precision medicine.
暂无分享,去创建一个
Yoon-Jae Cho | T. Laetsch | K. Janeway | J. G. Glade Bender | N. Takebe | C. Allen | N. Seibel | J. V. Tricoli | M. Irwin | S. Chi | A. Kim | D. W. Parsons | AeRang Kim
[1] O. Delattre,et al. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors , 2017, Pediatric blood & cancer.
[2] P. Raman,et al. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome , 2016, PLoS genetics.
[3] David T. W. Jones,et al. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.
[4] R. Gray,et al. Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis , 2016 .
[5] Tao Wang,et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.
[6] B. Crompton,et al. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. , 2016, JAMA oncology.
[7] Roman Rouzier,et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.
[8] Nallasivam Palanisamy,et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.
[9] Gudrun Schleiermacher,et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.
[10] Sven Rahmann,et al. Mutational dynamics between primary and relapse neuroblastomas , 2015, Nature Genetics.
[11] Yingdong Zhao,et al. Application of molecular profiling in clinical trials for advanced metastatic cancers. , 2015, Journal of the National Cancer Institute.
[12] F. Speleman,et al. Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] N. Heerema,et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 , 2014, Leukemia.
[14] J. Maris,et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.
[15] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[16] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[17] N. Heerema,et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Trevor J Pugh,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .